Of note, three orally active JAK2 inhibitors, ruxolitinib, baricitinib, and fedratinib, have been approved by the FDA for rheumatoid arthritis and myelofibrosis [15,16,17]; they are being evaluated for human cancers in numerous clinical trials. Here, JAK2 is linked to cancer.